The Wall Street Journal reports: The Food and Drug Administration approved a controversial drug for depression that could be the first of a long-awaited wave of new treatments, but that has also raised concerns about abuse. The drug, a nasal spray that manufacturer Johnson & Johnson JNJ 0.21% has branded Spravato, is a close chemical relation to ketamine. Ketamine is …
Read More »